Abstract:Misregulated alternative RNA splicing (AS) contributes to the tumorigenesis and progression of human cancers, including glioblastoma (GBM). Here, we showed that a major splicing factor, serine and arginine rich splicing factor 3 (SRSF3), was frequently upregulated in clinical glioma specimens and that elevated SRSF3 was associated with tumor progression and a poor prognosis for patients with glioma. In patient-derived glioma stem-like cells (GSC), SRSF3 expression promoted cell proliferation, self-renewal, and tumorigenesis. Transcriptomic profiling identified more than 1,000 SRSF3-affected AS events, with a preference for exon skipping in genes involved with cell mitosis. Motif analysis identified the sequence of CA(G/C/A)CC(C/A) as a potential exonic splicing enhancer for these SRSF3-regulated exons. To evaluate the biological impact of SRSF3-affected AS events, four candidates were selected whose AS correlated with SRSF3 expression in glioma tissues, and their splicing pattern was modified using a CRISPR/Cas9 approach. Two functionally validated AS candidates were further investigated for the mechanisms underlying their isoform-specific functions. Specifically, following knockout of SRSF3, transcription factor ETS variant 1 (ETV1) gene showed exon skipping at exon 7, while nudE neurodevelopment protein 1 (NDE1) gene showed replacement of terminal exon 9 with a mutually exclusive exon 9'. SRSF3-regulated AS of these two genes markedly increased their oncogenic activity in GSCs. Taken together, our data demonstrate that SRSF3 is a key regulator of AS in GBM and that understanding mechanisms of misregulated AS could provide critical insights for developing effective therapeutic strategies against GBMs. SIGNIFICANCE: SRSF3 is a significant regulator of glioma-associated alternative splicing, implicating SRSF3 as an oncogenic factor that contributes to the tumor biology of GBM.

Biological Function and Molecular Mechanism of SRSF3 in Cancer and Beyond (Review)

Oncogenic SRSF3 in Health and Diseases.

Emerging Roles of SRSF3 As a Therapeutic Target for Cancer

SRSF3 Functions As an Oncogene in Colorectal Cancer by Regulating the Expression of ArhGAP30

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

Targeting Splicing Factor SRSF6 for Cancer Therapy

A Genome Landscape of SRSF3-regulated Splicing Events and Gene Expression in Human Osteosarcoma U2OS Cells.

SRSF3 Suppresses RCC Tumorigenesis and Progression Via Regulating SP4 Alternative Splicing

SRSF3, a Splicer of the PKM Gene, Regulates Cell Growth and Maintenance of Cancer-Specific Energy Metabolism in Colon Cancer Cells

Factors affecting the expression and stability of full-length and truncated SRSF3 proteins in human cancer cells

SR Splicing Factors Promote Cancer Via Multiple Regulatory Mechanisms.

SRSF3 Promotes Angiogenesis in Colorectal Cancer by Splicing SRF

Towards Understandings of Serine/arginine-Rich Splicing Factors

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

SR proteins in cancer: function, regulation, and small inhibitor

SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma.

RSF1 in cancer: interactions and functions

Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma

Targeting Serine- and Arginine-Rich Splicing Factors to Rectify Aberrant Alternative Splicing.

SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes

Oncogenic Splicing Factor SRSF3 Regulates ILF3 Alternative Splicing to Promote Cancer Cell Proliferation and Transformation